Genmab ASGNMSF 95 FCF Margin % is -0.22% as of Mar. 2026. GuruFocus rates GNMSF with a GF Score™ of 95/100 and a GF Value™ of $343.48 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 960 Biotechnology companies, Genmab AS ranks better than 90.31% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Genmab AS's Free Cash Flow for the
three
months ended in Mar. 2026 was $-2 Mil. Genmab AS's Revenue for the
three
months ended in Mar. 2026 was $896 Mil. Therefore, Genmab AS's FCF Margin % for the quarter that ended in Mar. 2026 was -0.22%.
The historical rank and industry rank for Genmab AS's FCF Margin % or its related term are showing as below:
GNMSF'
s FCF Margin % Range Over the Past 10 Years
Min: 16.22 Med: 27.59 Max: 63.42
Current: 22.35
During the past 13 years, the highest FCF Margin % of Genmab AS was 63.42%. The lowest was 16.22%. And the median was 27.59%.
GNMSF's FCF Margin % is ranked better than 90.31% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs GNMSF: 22.35
Genmab AS FCF Margin % Related Terms
Genmab AS FCF Margin % Historical Data
* Premium members only.
The historical data trend for Genmab AS's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNMSF vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Genmab AS's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Genmab AS's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (GNMSF) has a FCF Margin % of -0.22% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Genmab AS and its competitors. Over the past decade, Genmab AS's FCF Margin % has ranged from 16.22 to 63.42. According to the industry distribution chart, Genmab AS ranks #93 out of 960 companies in the Biotechnology industry, placing it in the top 9.7%.
Is Genmab AS's FCF Margin % too high?
Genmab AS's current FCF Margin % is -0.22%. Over the past 10 years, this metric has ranged from a low of 16.22 to a high of 63.42. Based on the distribution chart, Genmab AS ranks #93 out of 960 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genmab AS has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #93 out of 960 companies for FCF Margin %. This places Genmab AS in the top 10% of its industry — outperforming the majority of peers. Historically, Genmab AS's own FCF Margin % has ranged from 16.22 to 63.42 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Genmab AS and its competitors. Genmab AS's current FCF Margin % is -0.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $343.48, compared to a current price of $257.44 — trading 25.1% below its estimated fair value. The current FCF Margin % is -0.22%. Genmab AS's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Genmab AS (GNMSF), the current FCF Margin % is -0.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (GNMSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of $257.44 is trading 25.1% below its estimated GF Value™ of $343.48.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for GNMSF:
FCF Margin %: -0.22%
GF Value™: $343.48 vs. price of $257.44 (25.1% below fair value)
No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score
Get the complete analysis for GNMSF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNMSF has been successfully added to your 
